No services found
No Products found
In therapeutic development, fully human antibodies are your safest bet for regulatory approval by FDA or EMEA. They reduce immunogenicity and adverse reactions in patients. With four distinct human antibody generation platforms (phage display, single B cell screening, hybridoma development, de novo antibody generation), we guarantee fully human antibodies for virtually any antigen.
Having the right platforms is important. But pairing them with top scientific minds is what truly makes the difference. At ProteoGenix, your project is handled by PhD-level experts or seasoned professionals with years of experience in antibody development. Their goal: design the most effective strategy from the start — so you can move faster and with confidence.
At ProteoGenix, our proprietary phage display platforms combined with the industry’s largest panel of high-diversity human antibody libraries—naïve or immune—allow us to deliver high-affinity sequences in just 1 month.
High-affinity antibodies are crucial for optimizing therapeutic efficacy and minimizing side effects. At ProteoGenix, we isolate these powerful blocking antibodies through:
If we don’t deliver binders, you don’t pay 100% of the service — it’s that simple. This isn’t just a promise, it’s our commitment to your success.
At ProteoGenix, you retain full ownership of your results. No licensing fees.
At ProteoGenix, we combine the power of AI-driven discovery, expert wet-lab execution, and one of the most diverse antibody generation platforms on the market. This unique synergy enables us to take on even your most complex R&D challenges with confidence. We’ve already supported our clients on demanding scientific projects, such as:
These are just a few examples of the scientifically complex projects where we delivered high-quality monoclonal antibodies. But we also support clients facing more operational constraints, including:
For each case, our experts design tailor-made strategies to align with your scientific goals and technical requirements. Got a project in mind? Let’s talk strategy.
At ProteoGenix, we don’t just develop antibodies—we ensure your success.
Don’t gamble on uncertain outcomes—choose ProteoGenix for guaranteed success!
ProteoGenix supported Trident Biopharm Solutions in developing a cocktail of neutralizing antibodies against COVID-19 variants.
ProteoGenix collaborated with Isar Bioscience to generate an anti-TREM-2 antibody for a novel Alzheimer’s therapy.
ProteoGenix assisted Brown University in discovering two anti-malaria antibodies using its proprietary platforms.
We have been working together with ProteoGenix since 2020. Using phage display, they helped our team to develop several antibodies with effective blocking effects. We are pleased with their services and look forward to continue working together with them as we advance our research and bring the biologics to the clinical stage.
Prof Johnny Ong Chin-Ann, MD, PhD, Group leader, National Cancer Centre, Singapore
I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage-Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns. During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemics evolved. Their proactivity was key to obtain promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.
Khelan Patel, Managing Director, Trident Biopharm Solutions, London, UK
We are developing a novel immunotherapy and needed a highly potent monoclonal antibody. Currently the development of a novel antibody requires lengthy and expensive humanization process. We thus decided to screen for binders via phage display screening instead using a human library. Proteogenix proposed just that. We provided our purified target antigen and in only one month several high affinity binders were obtained. We were able to quickly clone and produce a monoclonal antibody from the sequences provided. What should have taken 6 to 8 months was done in 2 for a fraction of the cost and for an equivalent quality.
Dr. Abbas El Sahili, Senior Research Fellow, Nanyang Technological University, Singapore
I requested ProteoGenix’s services for the generation of antibodies against a malarial protein by phage display. Their naive human library, which is comprised of 368 donors, is a unique resource which was one of the criteria I used to select their company. They optimized their standard screening strategy to be able to identify two specific clones, that they then expressed with very high yields in their proprietary XtenCHOTM cell line. I highly appreciated their level of expertise and their commitment to go beyond expectations, and I would recommend them for their reactivity and the high quality of their services.
Prof Jonathan Kurtis, MD, PhD, Chair, Department of Pathology and Laboratory Medicine, Brown University, USA
E Vidal-Calvo et al., Tumor-agnostic cancer therapy using antibodies targeting oncofetal chondroitin sulfate. Nature Communications 15, 7553 (2024). https://doi.org/10.1038/s41467-024-51781-0
H Cerutti et al., Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal 35, (4) 23735 (2021). https://doi.org/10.1002/jcla.23735
M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024). https://doi.org/10.3389/fimmu.2024.1520103
Christlmeier M, et al. Human anti-trem2 antibody for treating neurodegenerative disorders. WO2024160736A1. 2024 Aug 8. https://patents.google.com/patent/WO2024160736A1/en
You can learn more on this project here.
El Mazouari K. Human-like target-binding proteins. WO2023161448A1. 2023 Aug 31. https://patents.google.com/patent/WO2023161448A1/en
Maione F, et al. Novel interleukin-17a (il-17a)-derived peptide and neutralizing antibody (ab17-ipl-1). WO2024028436A1. 2024 Feb 8. https://patents.google.com/patent/WO2024028436A1/en
At ProteoGenix, timelines can vary depending on several factors:
As a general guideline:
Please note these timelines are indicative. For a personalized estimate, contact our experts.
Just like timelines, project cost depends on:
As a ballpark:
Thanks to our in vivo and in vitro discovery platforms, we offer broad target flexibility. We can generate antibodies against small molecules, peptides, soluble and membrane proteins (even in their native conformation using nanodisc technology), nucleic acids (DNA, RNA), and more—even when targets are toxic or poorly immunogenic.
We offer a wide range of monospecific formats, including full-length IgG, Fab fragments, scFv, and VHH/nanobodies from our dedicated libraries. We also engineer advanced formats such as bispecific antibodies, antibody-drug conjugates (ADCs), and Fc-fusion proteins
Choosing the right method can be complex — it largely depends on your project requirements, including your antigen’s characteristics, timelines, and budget. Want to explore your options? Check out our dedicated blog post. Looking for tailored advice? Our experts are here to help you find the best fit for your specific needs.
+1 919 234 1277
inquiry-mabs@proteogenix.fr
Contact us
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
Send
Your cart is currently empty.